Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, Jing Jing Han, Paula A. Schneider, Brian D. Koh, Mary J. Stenson, Linda E. Wellik, Jennifer C. Shing, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Sharon Barr, Thomas Elmer Witzig, Scott H Kaufmann

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027-induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027-induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, upregulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.

Original languageEnglish (US)
Pages (from-to)476-487
Number of pages12
JournalBlood
Volume119
Issue number2
DOIs
StatePublished - Jan 12 2012

Fingerprint

Puma
Sirolimus
Chemical activation
Apoptosis
Mantle-Cell Lymphoma
Cells
Neoplasms
Lymphoma
B-Cell Leukemia
Sezary Syndrome
Cell Line
Phosphorylation
Critical Pathways
Caspase 9
Cytotoxicity
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Transcriptional Activation
Genes
OSI 027

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. / Gupta, Mamta; Wahner Hendrickson, Andrea E; Yun, Seong Seok; Han, Jing Jing; Schneider, Paula A.; Koh, Brian D.; Stenson, Mary J.; Wellik, Linda E.; Shing, Jennifer C.; Peterson, Kevin L.; Flatten, Karen S.; Hess, Allan D.; Smith, B. Douglas; Karp, Judith E.; Barr, Sharon; Witzig, Thomas Elmer; Kaufmann, Scott H.

In: Blood, Vol. 119, No. 2, 12.01.2012, p. 476-487.

Research output: Contribution to journalArticle

Gupta, M, Wahner Hendrickson, AE, Yun, SS, Han, JJ, Schneider, PA, Koh, BD, Stenson, MJ, Wellik, LE, Shing, JC, Peterson, KL, Flatten, KS, Hess, AD, Smith, BD, Karp, JE, Barr, S, Witzig, TE & Kaufmann, SH 2012, 'Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies', Blood, vol. 119, no. 2, pp. 476-487. https://doi.org/10.1182/blood-2011-04-346601
Gupta, Mamta ; Wahner Hendrickson, Andrea E ; Yun, Seong Seok ; Han, Jing Jing ; Schneider, Paula A. ; Koh, Brian D. ; Stenson, Mary J. ; Wellik, Linda E. ; Shing, Jennifer C. ; Peterson, Kevin L. ; Flatten, Karen S. ; Hess, Allan D. ; Smith, B. Douglas ; Karp, Judith E. ; Barr, Sharon ; Witzig, Thomas Elmer ; Kaufmann, Scott H. / Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. In: Blood. 2012 ; Vol. 119, No. 2. pp. 476-487.
@article{7dc8ddd7e88045b4b03a77a772925fa2,
title = "Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies",
abstract = "The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027-induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027-induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, upregulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.",
author = "Mamta Gupta and {Wahner Hendrickson}, {Andrea E} and Yun, {Seong Seok} and Han, {Jing Jing} and Schneider, {Paula A.} and Koh, {Brian D.} and Stenson, {Mary J.} and Wellik, {Linda E.} and Shing, {Jennifer C.} and Peterson, {Kevin L.} and Flatten, {Karen S.} and Hess, {Allan D.} and Smith, {B. Douglas} and Karp, {Judith E.} and Sharon Barr and Witzig, {Thomas Elmer} and Kaufmann, {Scott H}",
year = "2012",
month = "1",
day = "12",
doi = "10.1182/blood-2011-04-346601",
language = "English (US)",
volume = "119",
pages = "476--487",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

AU - Gupta, Mamta

AU - Wahner Hendrickson, Andrea E

AU - Yun, Seong Seok

AU - Han, Jing Jing

AU - Schneider, Paula A.

AU - Koh, Brian D.

AU - Stenson, Mary J.

AU - Wellik, Linda E.

AU - Shing, Jennifer C.

AU - Peterson, Kevin L.

AU - Flatten, Karen S.

AU - Hess, Allan D.

AU - Smith, B. Douglas

AU - Karp, Judith E.

AU - Barr, Sharon

AU - Witzig, Thomas Elmer

AU - Kaufmann, Scott H

PY - 2012/1/12

Y1 - 2012/1/12

N2 - The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027-induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027-induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, upregulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.

AB - The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027-induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027-induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, upregulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84863393353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393353&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-04-346601

DO - 10.1182/blood-2011-04-346601

M3 - Article

VL - 119

SP - 476

EP - 487

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -